BPH Energy Ltd

BPH

BPH Energy Ltd. engages in investments in biotechnology and oil and gas exploration entities. The company is headquartered in Perth, Western Australia. The company went IPO on 2004-08-06. The firm holds a significant interest in an unlisted oil and gas exploration company. The Company’s principal activities include investments in various companies, which include Clean Hydrogen Technologies Corporation (Clean Hydrogen Technologies), Cortical Dynamics Limited (Cortical), Advent Energy Limited, and Molecular Discovery Systems Limited (MDSystems). Clean Hydrogen Technologies is a USA Delaware registered company with technology to produce clean hydrogen. The Advent Energy Limited is an unlisted oil and gas exploration and production company based in Perth, Western Australia. The Cortical is a medical device company focused on developing brain function monitors by employing theories and technologies in the field. MDSystems focuses on drug discovery and the validation of biomarkers for disease, therapy and diagnostics.

Core Lithium Ltd

CXO

Core Lithium Ltd. is an Australian based mineral exploration company, which engages in the acquisition, exploration, evaluation, and development of copper, gold, uranium, and iron ore properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2011-02-11. The company owns and operates Finniss Lithium project, which is located south of Darwin Port in the Northern Territory. The project lies within a prospective area for lithium in the NT, the Bynoe Pegmatite Field, and covers approximately 500 square kilometers (km2) of granted tenements. The project is approximately 88 kilometers (km) by sealed road from Darwin Port, Northern Territory. Its other projects include Shoobridge Lithium, Anningie and Barrow Creek Lithium, Napperby Uranium, Yerelina and Mt Freeling, and Blueys-Inkheart. The Shoobridge Lithium Project is located approximately 80 km south-southeast of Finniss near Darwin in the Northern Territory. The Anningie and Barrow Creek encompass eight exploration licenses over approximately 2,000 km2 in and around the Anningie and Barrow Creek tin-tantalum pegmatite fields in the Northern Territory. Napperby is an advanced uranium project within the central Northern Territory.

Global 100 Large-Caps (ex-AUS)

ETHI

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

Appen Limited

APX

Appen Ltd. engages in the development of human-annotated datasets for machine learning and artificial intelligence. The company is headquartered in Chatswood, New South Wales and currently employs 992 full-time employees. The company went IPO on 2015-01-07. The firm is engaged in providing data services for deep learning and generative artificial intelligence (AI) systems. The firm operates through two segments: Global Services and New Markets. The Global Services represent the services that the Company provides to its five United States technology customers (Global customers) using the customer's data annotation platforms and tools. New Markets comprise Appen's data annotation platform and tools (Global Product), and the enterprise, government, and China business units. New Markets also include Quadrant geolocation and Point-of-Interest (POI) data capabilities. Its Annotation Platform is the platform that both customers and internal teams used to design, run and manage data annotation tasks. The firm serves various industries, including technology, automotive, financial services, healthcare, retail, and government agencies.

Imugene

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.